Gilead Sciences Inc
NASDAQ: GILD
$89.88
+$0.74 (+0.8%)
Closing Price on January 10, 2025
GILD Articles
Merrill Lynch sees some stabilization in the hepatitis C market in 2016 that might allow Gilead Sciences to stay above water this year.
Published:
Last Updated:
Friday's top analyst calls include Best Buy, 3D Systems, Electronic Arts, Gilead Sciences, Nokia, Shire and United Rentals.
Published:
Last Updated:
The short interest data are out for the December 31 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
Published:
Last Updated:
This is going to be a big year in biotech, with a host of drugs set to undergo FDA scrutiny. These four companies with promising candidates all have dates with the agency this year.
Published:
Last Updated:
The top analyst calls for Wednesday, January 6, 2016, include Bluebird Bio, Check Point Software, Comcast, Eli Lilly, Hyatt Hotels, Lockheed Martin and Rite Aid.
Published:
Last Updated:
24/7 Wall St. is taking a look at the bottom line for companies in the S&P 500 going into 2016, and we have chosen some of the least expensive stocks for the year.
Published:
Last Updated:
The short interest data are out for the December 15 settlement date, and short interest continued to be mixed in these selected biotech stocks.
Published:
Last Updated:
New data suggests that the stock market's performance in 2015 was bolstered or supported by the largest S&P 500 companies buying back their own stock.
Published:
Last Updated:
Amgen is getting aggressive enough on its dividend payout that you might think the biotech giant is now just a Big Pharma stock.
Published:
Last Updated:
Over the past 10 years the single, most innovative company in the world has been Apple, according to the Boston Consulting Group.
Published:
Last Updated:
The November 30 short interest data have been compared with the previous report, and short interest was mixed in these selected stocks for this settlement date.
Published:
Last Updated:
24/7 Wall St. has reviewed the short interest data on the top biotech companies.
Published:
Last Updated:
Here are 10 stocks that could outperform the index funds from now to early February.
Published:
Last Updated:
Merck is joining the likes of Gilead Sciences in producing hepatitis C vaccines, but it is still in the early clinical stages.
Published:
Last Updated:
The short interest data are out for the October 30 settlement date, and short interest fell in selected biotech stocks.
Published:
Last Updated:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.